Special Issue "Cancer Signaling Pathways and Crosstalk"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (30 April 2011)
Dr. Don Benjamin
Growth & Development Unit, Rm. 583 Biozentrum, University of Basel, Klingelbergstrasse 50/70, CH-4056 Basel, Switzerland
Fax: +41 61 267 07 59
Interests: mTOR; cancer metabolism; glycolysis; signal transduction; mRNA stability
Cell signaling pathways regulate cell growth, proliferation and survival. Many common genetic lesions in cancer involve signaling proteins, either as activating mutations (Ras, PI3k, Akt) or loss of function of tumor suppressors (Pten). Hyperactivation of these pathways drives tumorigenesis and supports tumor growth and leads to the establishment of pathway addiction for a particular cancer. As signals are propagated along these pathways by a relay of protein kinases, this allows access to therapeutic intervention by specific kinase inhibitors that has proven to be clinically successful. While development of kinase inhibitors continues to be actively pursued, successful treatment requires correct targeting of specific inhibitors to tumors addicted to a particular pathway. To this end, much remains to be done in identifying biomarkers for pathway addiction, and crosstalk between parallel signaling pathways in identifying patients most likely to respond to specific inhibitors.